<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">LV3HDkrBDGZT5hqZqrkndJw</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012001000005</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09900100005</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012005000050</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Valor progn&#243;stico do pept&#237;deo natriur&#233;tico tipo B na mortalidade de pacientes com S&#237;ndrome Coronariana Aguda</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Scotti</surname>
            <given-names>Alexandre Vaz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tura</surname>
            <given-names>Bernardo Rangel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rocha</surname>
            <given-names>Ronilson Gon&#231;alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Albuquerque</surname>
            <given-names>Denilson Campos de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade do Estado do Rio de Janeiro</institution>
        <institution content-type="orgdiv1">Instituto DOr de Ensino e Pesquisa </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>07</month>
        <year>2012</year>
      </pub-date>
      <volume>99</volume>
      <issue>1</issue>
      <fpage>605</fpage>
      <lpage>612</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>10</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>08</day>
          <month>03</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>10</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O valor progn&#243;stico do PNB na S&#237;ndrome Coronariana Aguda (SCA) tem sido repetidamente avaliado, mas ainda n&#227;o completamente bem estabelecido. Os dados da literatura para estabelecer o melhor momento para avaliar o PNB, seja na admiss&#227;o hospitalar, seja ap&#243;s a interven&#231;&#227;o coronariana, s&#227;o controversos. OBJETIVO: Analisar o PNB em SCA sem supradesnivelamento do segmento ST (Scasest), no longo prazo, e avaliar a associa&#231;&#227;o entre PNB (pg/mL), morte, anatomia coronariana, e Escore de Risco TIMI. M&#201;TODOS: Quarenta pacientes com Scasest e troponina &gt; 0,50 ng/mL tiveram seus n&#237;veis de PNB medidos na admiss&#227;o e 96 horas depois, e foram acompanhados por quatro anos. A diferen&#231;a entre as duas medidas foi avaliada utilizando o teste de Wilcoxon (p &lt; 0,05). A curva ROC foi utilizada para avaliar o PNB de 96 horas preditor de morte, e a regress&#227;o log&#237;stica foi usada para avaliar um poss&#237;vel fator de confus&#227;o entre o PNB de 96 horas, a idade e o resultado. RESULTADOS: Havia um aumento no PNB de 96 horas (148 na admiss&#227;o contra 267 ap&#243;s 96 horas; p = 0,04). Treze pacientes morreram. Para o corte 300 pg/mL, o PNB de 96 horas foi um preditor de morte (sensibilidade, 92,30%; especificidade, 77,80%; valor preditivo positivo, 66,70%; valor preditivo negativo, 95,50%). A &#225;rea sob a curva ROC foi de 0,92. Foi observado um aumento de 7,4 vezes no risco relativo de morte em quatro anos com um PNB de 96 horas &gt; 300 pg/mL (95% CI 1,90 a 29,30 p &lt; 0,01). Foi observada uma associa&#231;&#227;o entre o PNB de 96 horas e o Escore de Risco TIMI (p &lt; 0,01). Foi observada uma associa&#231;&#227;o entre o aumento no PNB de 96 horas e a doen&#231;a multiarterial (p = 0,02). CONCLUS&#195;O: Na Scasest com troponina positiva, o PNB de 96 horas pode ser uma ferramenta de estratifica&#231;&#227;o de risco. (Arq Bras Cardiol. 2012; [online].ahead print, PP.0-0)</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Progn&#243;stico</kwd>
        <kwd>pept&#237;deos natriur&#233;ticos</kwd>
        <kwd>s&#237;ndrome coronariana aguda</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>29</day>
        <month>05</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>Valor progn&#243;stico do pept&#237;deo natriur&#233;tico tipo B na mortalidade de pacientes com S&#237;ndrome Coronariana Aguda</p>
    <p>
      <bold>Alexandre Vaz Scotti; Bernardo Rangel Tura; Ronilson Gon&#231;alves Rocha; Denilson Campos de Albuquerque</bold>
    </p>
    <p> Instituto DOr de Ensino e Pesquisa; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nota">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> O valor progn&#243;stico do PNB na S&#237;ndrome Coronariana Aguda (SCA) tem sido repetidamente avaliado, mas ainda n&#227;o completamente bem estabelecido. Os dados da literatura para estabelecer o melhor momento para avaliar o PNB, seja na admiss&#227;o hospitalar, seja ap&#243;s a interven&#231;&#227;o coronariana, s&#227;o controversos. </p>
    <p><bold>OBJETIVO:</bold> Analisar o PNB em SCA sem supradesnivelamento do segmento ST (Scasest), no longo prazo, e avaliar a associa&#231;&#227;o entre PNB (pg/mL), morte, anatomia coronariana, e Escore de Risco TIMI. </p>
    <p><bold>M&#201;TODOS:</bold> Quarenta pacientes com Scasest e troponina &gt; 0,50 ng/mL tiveram seus n&#237;veis de PNB medidos na admiss&#227;o e 96 horas depois, e foram acompanhados por quatro anos. A diferen&#231;a entre as duas medidas foi avaliada utilizando o teste de Wilcoxon (p &lt; 0,05). A curva ROC foi utilizada para avaliar o PNB de 96 horas preditor de morte, e a regress&#227;o log&#237;stica foi usada para avaliar um poss&#237;vel fator de confus&#227;o entre o PNB de 96 horas, a idade e o resultado. </p>
    <p><bold>RESULTADOS:</bold> Havia um aumento no PNB de 96 horas (148 na admiss&#227;o contra 267 ap&#243;s 96 horas; p = 0,04). Treze pacientes morreram. Para o corte 300 pg/mL, o PNB de 96 horas foi um preditor de morte (sensibilidade, 92,30%; especificidade, 77,80%; valor preditivo positivo, 66,70%; valor preditivo negativo, 95,50%). A &#225;rea sob a curva ROC foi de 0,92. Foi observado um aumento de 7,4 vezes no risco relativo de morte em quatro anos com um PNB de 96 horas &gt; 300 pg/mL (95% CI 1,90 a 29,30 p &lt; 0,01). Foi observada uma associa&#231;&#227;o entre o PNB de 96 horas e o Escore de Risco TIMI (p &lt; 0,01). Foi observada uma associa&#231;&#227;o entre o aumento no PNB de 96 horas e a doen&#231;a multiarterial (p = 0,02). </p>
    <p><bold>CONCLUS&#195;O:</bold> Na Scasest com troponina positiva, o PNB de 96 horas pode ser uma ferramenta de estratifica&#231;&#227;o de risco. (Arq Bras Cardiol. 2012; [online].ahead print, PP.0-0)</p>
    <p><bold>Palavras-chave</bold>: Progn&#243;stico, pept&#237;deos natriur&#233;ticos, s&#237;ndrome coronariana aguda / mortalidade.</p>
    <p>
      <bold>Introdu&#231;&#227;o </bold>
    </p>
    <p>Nos Estados Unidos e na Europa, cerca de quinze milh&#245;es de pessoas s&#227;o admitidas nas unidades de emerg&#234;ncia a cada ano com sintomas sugestivos de S&#237;ndrome Coronariana Aguda (SCA)<sup>1</sup>. A s&#237;ndrome coronariana aguda &#233; caracterizada por complexidade e m&#250;ltiplas causas fisiopatol&#243;gicas, tais como a ruptura da placa com trombose aguda, obstru&#231;&#227;o mec&#226;nica progressiva, angina inst&#225;vel secund&#225;ria, inflama&#231;&#227;o e obstru&#231;&#227;o din&#226;mica (vasospasmo coron&#225;rio)<sup>2</sup>.</p>
    <p>A estrat&#233;gia de m&#250;ltiplos marcadores tem sido recentemente estudada para avaliar a SCA e inclui, al&#233;m da troponina como um indicador de necrose mioc&#225;rdica, outros elementos, tais como pept&#237;deos natriur&#233;ticos (PNB e NT pr&#243;-PNB) como marcadores de estresse hemodin&#226;mico, prote&#237;nas C-reativas como marcador de atividade inflamat&#243;ria, e depura&#231;&#227;o de creatinina com indicador de les&#227;o endotelial<sup>3</sup>.</p>
    <p>Com o objetivo de refinar o progn&#243;stico e orientar as interven&#231;&#245;es cl&#237;nicas, Antman e cols.<sup>4</sup> propuseram a pontua&#231;&#227;o conhecida como Escore de Risco TIMI para pacientes com SCA. A sinergia desse conjunto de marcadores poderia constituir uma ferramenta &#250;til para compreender o progn&#243;stico de uma s&#237;ndrome t&#227;o heterog&#234;nea. O uso de estat&#237;sticas para analisar o progn&#243;stico previsto pelo PNB e NT pr&#243;-PNB tem sido demonstrado em SCA sem supradesnivelamento do segmento ST (Scasest), incluindo pacientes com nenhuma evid&#234;ncia cl&#237;nica de insufici&#234;ncia ventricular esquerda, nem de aumento de marcadores de necrose mioc&#225;rdica (troponina)<sup>5-6</sup>. Estudos t&#234;m demonstrado o potencial de PNB e NT pr&#243;-PNB para fornecer informa&#231;&#245;es adicionais aos marcadores tradicionais de les&#245;es subendoc&#225;rdicas ou subepic&#225;rdicas isqu&#234;micas no eletrocardiograma e avalia&#231;&#227;o de altera&#231;&#245;es na motilidade regional da parede lateral do ventr&#237;culo esquerdo em 1D/2D, em ecocardiografia transtor&#225;cica e de necrose mioc&#225;rdica (troponina) em SCA<sup>7</sup>.</p>
    <p>Considerando a heterogeneidade das SCA e seu impacto sobre a mortalidade no mundo e no Brasil, o presente estudo sugere o uso rotineiro do PNB ap&#243;s a interven&#231;&#227;o coronariana para a estratifica&#231;&#227;o de risco na Scasest com troponina positiva, avaliando o valor desse pept&#237;deo no progn&#243;stico de longo prazo de pacientes com alto risco. </p>
    <p>Al&#233;m disso, este estudo avalia a exist&#234;ncia de uma associa&#231;&#227;o entre o PNB e a anatomia das tr&#234;s art&#233;rias coronarianas, bem como a associa&#231;&#227;o entre o PNB e o Escore de Risco TIMI. </p>
    <p>
      <bold>Metodologia</bold>
    </p>
    <p>
      <bold>Popula&#231;&#227;o do estudo</bold>
    </p>
    <p>Este estudo de um &#250;nico centro avaliou 46 pacientes consecutivos, com alto risco de Scasest e troponina positiva, admitidos na Unidade de Dor Tor&#225;cica (UDT) do Hospital Copa D&#8217;Or, na cidade do Rio de Janeiro, Brasil, de maio de 2003 a janeiro de 2004. Seis pacientes foram exclu&#237;dos do estudo pelo que segue: dois por causa de &#243;bito nas primeiras 96 horas ap&#243;s a admiss&#227;o, e quatro por n&#227;o sofrerem estratifica&#231;&#227;o invasiva. Quarenta pacientes completaram o estudo.</p>
    <p>O acompanhamento do estudo contemplou um per&#237;odo de quatro anos ap&#243;s a sele&#231;&#227;o dos pacientes e consistiu na realiza&#231;&#227;o de um question&#225;rio por telefone, de seis em seis meses. No caso de um evento anormal, os pesquisadores do estudo foram notificados para que pudessem avaliar o evento. Este estudo foi aprovado pelo Comit&#234; de &#201;tica em Pesquisa da institui&#231;&#227;o.</p>
    <p>
      <bold>Sele&#231;&#227;o dos pacientes</bold>
    </p>
    <p>Durante a consulta inicial na unidade de emerg&#234;ncia, foram considerados os seguintes crit&#233;rios de inclus&#227;o: </p>
    <p>a) Presen&#231;a de Scasest e aumento de troponina I (&gt; 0,5 ng/mL)<sup>8</sup> como fator de alto risco; </p>
    <p> b) A admiss&#227;o na UDT e transfer&#234;ncia para a Unidade de Terapia Intensiva Card&#237;aca nas primeiras 24 horas do in&#237;cio dos sintomas, com monitoramento do progresso; </p>
    <p> c) Estratifica&#231;&#227;o invasiva nas primeiras 24 horas ap&#243;s a admiss&#227;o; </p>
    <p> d) Assinatura do termo de consentimento informado.</p>
    <p>Depois disso, foram solicitados testes complementares e definida a estrat&#233;gia de tratamento.</p>
    <p>Os crit&#233;rios de exclus&#227;o foram:</p>
    <p>a) Contraindica&#231;&#227;o para estudo angiogr&#225;fico ou indica&#231;&#227;o do tratamento conservador pelo m&#233;dico tratante; </p>
    <p> b) Morte nas primeiras 96 horas ap&#243;s a admiss&#227;o; </p>
    <p> c) Presen&#231;a de doen&#231;a das valvas card&#237;acas concomitante; </p>
    <p> d) Insufici&#234;ncia renal definida como depura&#231;&#227;o de creatinina estimada &lt; 50 mL/min, calculado pelo uso da f&#243;rmula de Cockroft-Gault<sup>9</sup>; </p>
    <p> e) A disfun&#231;&#227;o ventricular esquerda (FE &#8804; 50% pela regra de Simpson), sintom&#225;tica ou n&#227;o.</p>
    <p>
      <bold>Procedimentos</bold>
    </p>
    <p>Coleta de amostras de sangue para avaliar o PNB e a troponina I. As amostras de sangue foram coletadas para medir o PNB na admiss&#227;o e ap&#243;s 96 horas. As 96 horas ap&#243;s a admiss&#227;o hospitalar foram definidas como o per&#237;odo em que o PNB poderia indicar o produto final de interven&#231;&#227;o coronariana, sendo, ent&#227;o, uma ferramenta mais espec&#237;fica para analisar o progn&#243;stico no longo prazo, que o PNB na admiss&#227;o. Foi utilizado o ensaio de imunofluoresc&#234;ncia teste Triage PNB (Biosite Diagnostics, San Diego, CA, EUA). </p>
    <p>A troponina I foi avaliada na admiss&#227;o e quatro horas depois usando um m&#233;todo enzim&#225;tico (kit Dade Behring) e o dispositivo Immulite. O maior valor foi considerado para o estudo. O valor de refer&#234;ncia adotado foi &lt; 0,5 ng/mL.</p>
    <p>O Escore de Risco TIMI<sup>4</sup> dos pacientes foi calculado pela soma dos pontos, de acordo com o hist&#243;rico m&#233;dico e a apresenta&#231;&#227;o cl&#237;nica. </p>
    <p>Os fatores de risco para DAC, como hipertens&#227;o arterial sist&#234;mica, diabete melito, dislipidemia, obesidade e tabagismo, t&#234;m sido bem definidos na literatura m&#233;dica<sup>10</sup>.</p>
    <p>O ECG de 12 deriva&#231;&#245;es foi realizado na admiss&#227;o e quatro horas depois. Pacientes com supradesnivelamento do segmento ST no ECG foram exclu&#237;dos. Mais tarde, o ECG foi repetido diariamente durante a interna&#231;&#227;o Unidade de Terapia Intensiva Card&#237;aca.</p>
    <p>Todos os pacientes realizaram ecocardiograma transtor&#225;cico nas primeiras 12 horas de interna&#231;&#227;o, de acordo com o protocolo de dor tor&#225;cica da institui&#231;&#227;o onde foi realizado o estudo.</p>
    <p>A estratifica&#231;&#227;o invasiva com cineangiocoronariografia foi realizada dentro das primeiras 24 horas ap&#243;s a admiss&#227;o. </p>
    <p>Uma les&#227;o do tronco da coron&#225;ria esquerda &#8805; 50%, ou uma les&#227;o proximal das art&#233;rias coronarianas, Descendente Anterior (DA) e Circunflexa (CX), &#8805; 70% foi considerado correspondente a uma extensa &#225;rea mioc&#225;rdica em risco de isquemia e doen&#231;a multiarterial.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>O teste de Wilcoxon foi utilizado com um intervalo de confian&#231;a de 95% e um valor de p &lt;0,05 foi considerado significativo para analisar os n&#237;veis de PNB na admiss&#227;o e 96 horas depois. </p>
    <p>O teste do qui-quadrado de Pearson foi utilizado para analisar poss&#237;veis caracter&#237;sticas cl&#237;nicas envolvidas com o resultado. A curva ROC foi utilizada para identificar o melhor ponto de corte do PNB como preditor de morte card&#237;aca. </p>
    <p>A regress&#227;o log&#237;stica foi usada para avaliar um poss&#237;vel fator de confus&#227;o entre o PNB de 96 horas, a idade e o resultado.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>A popula&#231;&#227;o deste estudo consistiu em 40 pacientes (homens, 55,00%), com m&#233;dia de idade de 69,08 &#177; 11,40 anos. A <xref ref-type="table" rid="t1">tabela 1</xref> mostra as caracter&#237;sticas cl&#237;nicas, eletrocardiogr&#225;ficas e ecocardiogr&#225;ficas do grupo estudado. Em rela&#231;&#227;o &#224; estrat&#233;gia terap&#234;utica no momento da admiss&#227;o hospitalar, 23 pacientes foram submetidos a angioplastia coronariana, dez pacientes foram submetidos a revasculariza&#231;&#227;o mioc&#225;rdica, e sete pacientes foram submetidos a apenas tratamento cl&#237;nico.</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt01.jpg"/></table-wrap>
    <p>O Escore de Risco TIMI de 75,00% dos pacientes variou de 4 a 6, confirmando o perfil de risco dos pacientes neste estudo.</p>
    <p>Foi observada uma clara associa&#231;&#227;o entre o Escore de Risco TIMI com o PNB de 96 horas (p &lt; 0,01), mas n&#227;o com o valor de PNB medido na admiss&#227;o. </p>
    <p>A <xref ref-type="fig" rid="aop04612_port_f1">figura 1</xref> exibe um gr&#225;fico que demonstra claramente a associa&#231;&#227;o entre o Escore de Risco TIMI e o valor de PNB de 96 horas.</p>
    <p content-type="asset">
      <fig id="aop04612_port_f1">
        <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gf01.jpg"/></fig>
    </p>
    <p>Analisando as angiografias coronarianas, 24 (60,00%) atenderam os crit&#233;rios acima especificados para uma extensa &#225;rea mioc&#225;rdica em risco de isquemia, enquanto em 16 (40,00%) as angiografias coronarianas careciam desse achado. </p>
    <p>Na presen&#231;a de uma extensa &#225;rea do mioc&#225;rdio em risco de isquemia (<xref ref-type="table" rid="aop04612_pot_t2">tab. 2</xref>), foi observado um aumento importante na preval&#234;ncia da disfun&#231;&#227;o segmentar em ecocardiografia (p = 0,03), al&#233;m de altera&#231;&#245;es no ECG sugestivas de isquemia mioc&#225;rdica (p = 0,01).</p>
    <p content-type="asset">
      <table-wrap id="aop04612_pot_t2">
        <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt02.jpg"/></table-wrap>
    </p>
    <p>Comparando os dois valores de PNB (na admiss&#227;o e ap&#243;s 96 horas) e a anatomia da art&#233;ria coronariana, foi observada uma diferen&#231;a significativa (p = 0,02) nos valores de PNB (na admiss&#227;o e ap&#243;s 96 horas) no grupo de pacientes com uma extensa &#225;rea do mioc&#225;rdio em risco de isquemia. Por sua vez, no grupo de pacientes sem danos no tronco da coron&#225;ria esquerda ou seu equivalente, n&#227;o houve diferen&#231;a significativa nos valores de PNB (p = 0,06) (<xref ref-type="fig" rid="aop04612_port_f2">fig. 2</xref>).</p>
    <p content-type="asset">
      <fig id="aop04612_port_f2">
        <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gf02.jpg"/></fig>
    </p>
    <p>Durante os quatro anos de acompanhamento, treze pacientes morreram, quatro deles por morte s&#250;bita. Os outros nove pacientes morreram durante a hospitaliza&#231;&#227;o por recorr&#234;ncia da SCA; as causas de morte foram as seguintes: sepse, cinco pacientes; acidente vascular encef&#225;lico, dois; infarto enteromesent&#233;rico, um; e insufici&#234;ncia card&#237;aca, um paciente. </p>
    <p>Comparando os achados cl&#237;nicos e eletrocardiogr&#225;ficos dos pacientes falecidos e dos pacientes vivos ap&#243;s quatro anos de acompanhamento, apenas a idade mais avan&#231;ada p&#244;de ser relacionada com o resultado de morte (<xref ref-type="table" rid="aop04612_port_t3">tab. 3</xref>). A curva ROC mostrou que o ponto de corte do PNB de 96 horas de 300,00 pg/mL diferenciou mais claramente os pacientes com maior risco de morte durante os quatro anos do acompanhamento. Para esse ponto de corte, a sensibilidade foi 92,30%; a especificidade foi 77,80%; o valor preditivo positivo foi 66,70%; e o valor preditivo negativo foi 95,50%. </p>
    <p content-type="asset">
      <table-wrap id="aop04612_port_t3">
        <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt03.jpg"/></table-wrap>
    </p>
    <p>A &#225;rea sob a curva foi de 0,92, (95% CI 90,20&#8594;94,80; p &lt; 0,01), indicando uma boa precis&#227;o (<xref ref-type="fig" rid="aop04612_port_f3">fig. 3</xref>). </p>
    <p content-type="asset">
      <fig id="aop04612_port_f3">
        <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gf03.jpg"/></fig>
    </p>
    <p>A regress&#227;o log&#237;stica foi usada para avaliar um poss&#237;vel fator de confus&#227;o entre idade, PNB e resultado. Para cada aumento de dez anos na idade, n&#227;o se observou contribui&#231;&#227;o para o resultado morte. Contudo, o PNB de 96 horas provou ser um preditor de mortalidade importante para o ponto de corte de 300 pg/mL, com uma taxa de risco dez vezes maior (<xref ref-type="table" rid="aop04612_port_t4">tab. 4</xref>). A an&#225;lise da precis&#227;o da precis&#227;o do PNB na admiss&#227;o, ou seja, dentro de 24 horas ap&#243;s o evento coronariano, n&#227;o chegou a ser significativa. A avalia&#231;&#227;o do ponto de corte de 274 pg/mL resultou em sensibilidade de 46,20%, especificidade de 85,20%, valor preditivo positivo de 60,00%, e valor preditivo negativo de 76,70%. A &#225;rea sob a curva foi de 0,65, o que n&#227;o indica uma boa precis&#227;o. Como o PNB de 96 horas representa o resultado final da interven&#231;&#227;o terap&#234;utica, acreditamos que, em nosso estudo, o PNB de 96 horas pode ser mais espec&#237;fico que o PNB na admiss&#227;o para a associa&#231;&#227;o com o progn&#243;stico de longo prazo. </p>
    <p content-type="asset">
      <table-wrap id="aop04612_port_t4">
        <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt04.jpg"/></table-wrap>
    </p>
    <p>Observou-se um risco relativo de 7,44 (95% CI 1,89&#8594;29,28) no grupo de pacientes com PNB de 96 horas superior a 300,00 pg/mL. No entanto, encontramos um CI grande; talvez com um n&#250;mero mais significativo de pacientes pudesse ser estabelecida uma melhor associa&#231;&#227;o com os nossos achados. </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O presente estudo mostrou que o PNB medido 96 horas ap&#243;s a admiss&#227;o, usando 300 pg/mL como ponto de corte, associado ao significativo risco relativo de morte de 7,44 (95% CI 1,89&#8594;29,28) durante os quatro anos de acompanhamento. A &#225;rea sob a curva ROC foi de 0,92, o que demonstra uma boa precis&#227;o. Esse achado est&#225; de acordo com outros estudos da literatura<sup>11-15</sup>, mostrando o poder estat&#237;stico e a import&#226;ncia dos pept&#237;deos natriur&#233;ticos como preditores de morte card&#237;aca em pacientes com SCA.</p>
    <p>A idade foi a &#250;nica vari&#225;vel que p&#244;de ser associada com o resultado, embora n&#227;o se saiba da exist&#234;ncia de rela&#231;&#227;o entre faixa et&#225;ria e altos n&#237;veis s&#233;ricos de PNB. Al&#233;m disso, a an&#225;lise de regress&#227;o log&#237;stica demonstrou que a idade, o PNB de 96 horas, e os resultados n&#227;o est&#227;o associadas.</p>
    <p>Considerando-se o ponto de corte de 300 pg/mL do PNB de 96 horas, a <xref ref-type="table" rid="aop04612_port_t4">tabela 4</xref> mostra uma taxa de risco dez vezes maior para cada dez anos de aumento na idade.</p>
    <p>Vale ressaltar que a an&#225;lise da precis&#227;o do PNB na admiss&#227;o n&#227;o poderia discriminar um ponto de corte significativo para estimar o risco de eventos durante o per&#237;odo de acompanhamento. Isso n&#227;o foi observado no estudo de Bassan e cols.<sup>12</sup>, que usou o PNB na admiss&#227;o para distinguir o ponto de corte como preditor de mortalidade precoce e tardio.</p>
    <p>A nossa hip&#243;tese &#233; de que o PNB de 96 horas pode ser um marcador mais compat&#237;vel com o mundo real, no longo prazo, porque &#233; o resultado final da abordagem terap&#234;utica. Como todos os pacientes neste estudo foram submetidos a interven&#231;&#227;o coronariana dentro das primeiras 24 horas ap&#243;s o evento isqu&#234;mico, no final das 96 horas todos os pacientes tinham sido tratados, isto &#233;, as estrat&#233;gias terap&#234;uticas j&#225; tinham sido definidas. No entanto, estudos posteriores, especialmente com um n&#250;mero mais significativo de pacientes, deveriam ser realizados para confirmar essa hip&#243;tese.</p>
    <p>Eggers e cols.<sup>15</sup> relataram uma precis&#227;o excelente de NT pr&#243;-PNB medido no final do curso da SCA (&#224;s seis semanas e ap&#243;s seis meses). Assim, al&#233;m de serem preditores de morte quando medidos durante a hospitaliza&#231;&#227;o, uma vez que os pept&#237;deos natriur&#233;ticos podem indicar a &#225;rea isqu&#234;mica, eles podem tamb&#233;m adicionar informa&#231;&#227;o progn&#243;stica, quando analisados ap&#243;s a defini&#231;&#227;o de tratamento. </p>
    <p>O presente estudo tamb&#233;m avaliou as poss&#237;veis associa&#231;&#245;es entre o Escore de Risco TIMI e valores de PNB na admiss&#227;o e 96 horas depois. </p>
    <p>Uma clara associa&#231;&#227;o foi observada entre o PNB de 96 horas e um aumento no Escore de Risco TIMI. Analisando o gr&#225;fico da referida associa&#231;&#227;o (<xref ref-type="fig" rid="aop04612_port_f1">fig. 1</xref>), a queda observada pode resultar do n&#250;mero reduzido de indiv&#237;duos com um Escore de Risco TIMI de 6. Acreditamos tamb&#233;m que o PNB de 96 horas agiu como um marcador de progn&#243;stico adicional para o Escore de Risco TIMI, que &#233; uma ferramenta de estratifica&#231;&#227;o de risco bem definida para a Scasest no curto e longo prazo<sup>4</sup>. No entanto, dois estudos publicados recentemente tamb&#233;m t&#234;m demonstrado o maior valor progn&#243;stico do NT pr&#243;-PNB, quando comparado com o do Escore de Risco TIMI<sup>16,17</sup>.</p>
    <p>A literatura carece de crit&#233;rios uniformes para a quantifica&#231;&#227;o da &#225;rea isqu&#234;mica do mioc&#225;rdio em termos de valores de PNB. Os dois principais estudos de Sadanandan e cols.<sup>18</sup> e Ndrepepa e cols. <sup>19</sup> utilizaram, como crit&#233;rios para estimar a &#225;rea do mioc&#225;rdio em risco de isquemia, os efeitos sobre a art&#233;ria coronariana descendente anterior e a anatomia das tr&#234;s art&#233;rias, respectivamente.</p>
    <p>Em nossa casu&#237;stica, o aumento nos valores do PNB 96 horas ap&#243;s a interna&#231;&#227;o e interven&#231;&#227;o coronariana indicou pacientes com grandes &#225;reas de mioc&#225;rdio em risco de isquemia e doen&#231;a multiarterial. As altera&#231;&#245;es eletrocardiogr&#225;ficas, diminui&#231;&#227;o do segmento ST e/ou invers&#227;o de onda T, e altera&#231;&#245;es ecocardiogr&#225;ficas, disfun&#231;&#227;o segmentar, compat&#237;vel com isquemia mioc&#225;rdica foram mais prevalentes no grupo de pacientes com doen&#231;a multiarterial (<xref ref-type="table" rid="aop04612_pot_t2">tab. 2</xref>).</p>
    <p>Os estudos anteriores mostraram que um aumento acentuado nos n&#237;veis s&#233;ricos do PNB durante um evento isqu&#234;mico, sem evid&#234;ncia de disfun&#231;&#227;o sist&#243;lica, pode ser associado &#224; complexidade e gravidade da anatomia da art&#233;ria coronariana. Por exemplo, Sabatine e cols.<sup>20</sup> t&#234;m relatado, durante a isquemia do mioc&#225;rdio transit&#243;ria, um aumento significativo nos n&#237;veis s&#233;ricos de BNP, e o aumento foi associado com a gravidade da doen&#231;a isqu&#234;mica. </p>
    <p>Em nosso estudo, foi observado um aumento significativo no n&#237;vel do PNB 96 horas ap&#243;s a admiss&#227;o (p = 0,02) na popula&#231;&#227;o com maiores &#225;reas de mioc&#225;rdio em risco de isquemia e doen&#231;a multiarterial. Decidimos n&#227;o usar um ponto de corte, porque j&#225; t&#237;nhamos os n&#237;veis de PNB na admiss&#227;o e ap&#243;s 96 horas, assim a import&#226;ncia do aumento durante o per&#237;odo foi avaliada. </p>
    <p>&#201; interessante notar que, em nossa casu&#237;stica, os n&#237;veis de PNB encontrados foram superiores aos relatados na literatura. Analisando alguns estudos anteriores, observamos que o ponto de corte do PNB foi modificado, dependendo da finalidade do projeto de pesquisa. Para o diagn&#243;stico de insufici&#234;ncia card&#237;aca, um ponto de corte de 200 pg/mL &#233; extremamente preciso<sup>21</sup>. Em pacientes com dor tor&#225;cica, o PNB &gt;100 pg/mL &#233; um forte preditor de infarto agudo do mioc&#225;rdio<sup>22</sup>. Para pacientes com Scasest, n&#237;veis s&#233;ricos de PNB acima de 80 pg/mL poderiam estar associados com a gravidade e extens&#227;o da &#225;rea isqu&#234;mica do mioc&#225;rdio<sup>18</sup>.</p>
    <p>No presente estudo, um ponto de corte 300-pg/mL para PNB de 96 horas poderia ser o PNB que representa o resultado de interven&#231;&#227;o coronariana, definido um grupo de pacientes com Scasest mais severa e um risco 7,4 vezes maior de morte nos quatro anos de acompanhamento.</p>
    <p>Em um estudo recentemente publicado com o objetivo de analisar o progn&#243;stico de pacientes com Scasest, um ponto de corte do PNB na admiss&#227;o de 101 pg/mL discriminou um risco relativo de morte de 13,0 no primeiro m&#234;s e de 5,3 em um ano<sup>12</sup>.</p>
    <p>Outro estudo relatou a associa&#231;&#227;o entre o NT pr&#243;-PNB e o resultado de morte no prazo de seis anos de acompanhamento em pacientes com SCA e ap&#243;s revasculariza&#231;&#227;o mioc&#225;rdica<sup>23</sup>.</p>
    <p>O PNB de 96 horas poderia ser um complemento &#250;til, ferramenta de f&#225;cil calibra&#231;&#227;o para a estratifica&#231;&#227;o de risco em pacientes com SCA, especialmente em locais desprovidos de instala&#231;&#245;es laboratoriais hemodin&#226;micas, permitindo o f&#225;cil reconhecimento dos grupos com maior risco de eventos adversos tardios.</p>
    <p>O presente estudo sugere que um aumento no n&#237;vel de PNB de 96 horas (&gt; 300 pg/mL) est&#225; associado a um maior risco de morte durante os quatro anos de acompanhamento, em pacientes com Scasest. Isso requer um monitoramento cl&#237;nico rigoroso para ajustar os fatores de risco cardiovascular. No entanto, a literatura ainda carece de dados que justifiquem o uso de uma estrat&#233;gia de tratamento baseado apenas na eleva&#231;&#227;o dos n&#237;veis de PNB em pacientes com SCA. </p>
    <p>&#201; f&#225;cil entender o aumento do PNB nos pacientes com SCA com disfun&#231;&#227;o mioc&#225;rdica, porque o aumento da press&#227;o de enchimento ventricular esquerdo dispara a s&#237;ntese e libera&#231;&#227;o do PNB<sup>24-26</sup>. Contudo, o aumento do risco de um evento card&#237;aco numa popula&#231;&#227;o sem fal&#234;ncia ventricular esquerda sugere a exist&#234;ncia de outros mecanismos. A disfun&#231;&#227;o diast&#243;lica secund&#225;ria &#224; isquemia do mioc&#225;rdio pode ser um dos fatores por tr&#225;s do aumento nos n&#237;veis s&#233;ricos de PNB em SCA<sup>27,28</sup>.</p>
    <p>O PNB de 96 horas tamb&#233;m deve ser interpretado juntamente com achados hemodin&#226;micos e cl&#237;nicos, altera&#231;&#245;es eletrocardiogr&#225;ficas, eleva&#231;&#227;o de marcadores de necrose mioc&#225;rdica [massa de creatina quinase (CK) e troponina], presen&#231;a de altera&#231;&#245;es segmentares no ecocardiograma transtor&#225;cico e perfil inflamat&#243;rio, utilizando medidas de PCR.</p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>O presente estudo tem certas limita&#231;&#245;es. O pequeno tamanho da amostra poderia resulta em um vi&#233;s de sele&#231;&#227;o. O crit&#233;rio escolhido para determinar a extens&#227;o da &#225;rea do mioc&#225;rdio em risco de isquemia, que era les&#227;o do tronco da coron&#225;ria esquerda e/ou seu equivalente, utilizou o grau de obstru&#231;&#227;o da art&#233;ria como par&#226;metro de isquemia, em vez da avalia&#231;&#227;o funcional. No entanto, devido &#224; gravidade cl&#237;nica do grupo estudado, a avalia&#231;&#227;o mediante cintilografia mioc&#225;rdica ou de resson&#226;ncia magn&#233;tica card&#237;aca, que poderiam ser prejudiciais para os pacientes, n&#227;o foi realizada.</p>
    <p>Este estudo foi realizado em uma institui&#231;&#227;o particular em um bairro pr&#243;spero da cidade do Rio de Janeiro, com pacientes de alto n&#237;vel socioecon&#244;mico e cultural. Assim, o risco pode ter sido subestimado, porque as condi&#231;&#245;es reais, tais como o acesso a recursos m&#233;dicos e medicamentos que interferem com o curso da doen&#231;a, n&#227;o foram consideradas na an&#225;lise. </p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>1. Em pacientes com Scasest, um n&#237;vel de BNP maior que 300 pg/mL 96 horas ap&#243;s o in&#237;cio de evento isqu&#234;mico e de interven&#231;&#227;o coronariana est&#225; associado com um risco 7,44 vezes maior de morte em quatro anos.</p>
    <p>2. No presente estudo, o maior aumento no n&#237;vel de PNB no prazo de 96 horas da admiss&#227;o est&#225; associado com uma maior gravidade na les&#227;o da art&#233;ria coronariana em pacientes com Scasest. Essa associa&#231;&#227;o poderia explicar a associa&#231;&#227;o entre o PNB de 96 horas e o evento Scasest.</p>
    <p>3. Nossos achados sugerem que pode haver uma associa&#231;&#227;o entre o PNB e o Escore de Risco TIMI.</p>
    <p>4. O PNB de 96 horas pode ser uma ferramenta &#250;til para o cardiologista para estabelecer o progn&#243;stico de longo prazo de pacientes com Scasest. No entanto, mais estudos s&#227;o necess&#225;rios para confirmar o melhor momento para avaliar o PNB (seja na admiss&#227;o ou ap&#243;s a interven&#231;&#227;o) durante a hospitaliza&#231;&#227;o de indiv&#237;duos com Scasest e troponina positiva. </p>
    <p>
      <bold>Agradecimentos</bold>
    </p>
    <p>Agradecemos ao Hospital Copa D&#8217;Or o apoio na coleta seriada de sangue e o financiamento deste estudo. Agradecemos tamb&#233;m aos pacientes e suas fam&#237;lias por fornecerem os seus dados cl&#237;nicos, contribuindo assim para</p>
    <p>
      <fn id="nota" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia</bold>
        </label>
        <p>: </p>
        <p> Alexandre Vaz Scotti </p>
        <p> Visconde de Piraj&#225; 623 - sala 804 &#8211; Ipanema - 22410-003 &#8211; Rio de Janeiro, RJ - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="alexandre.vaz.scotti@terra.com.br">alexandre.vaz.scotti@terra.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 21/10/11 </p>
    <p> Revisado recebido em 21/10/11 </p>
    <p> Aceito em 08/03/12.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1.    Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Avil&#233;s FF, et al.    Guidelines for the diagnosis and treatment of non-ST segment elevation acute    coronary syndromes. Eur Heart J. 2007;28(13):1598-660.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1598</fpage>
          <lpage>660</lpage>
          <issue>13</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bassand</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Hamm</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Ardissino</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Boersma</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Budaj</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Avil&#233;s</surname>
              <given-names>FF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2.      Braunwald E. Unstable angina: an etiologic approach to management. Circulation.      1998;98(21):2219-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Unstable angina: an etiologic approach to management</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2219</fpage>
          <lpage>22</lpage>
          <issue>21</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3.      Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes:      moving toward a multimarkers strategy. Circulation. 2003;108(3):250-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>uture of biomarkers in acute coronary syndromes: moving toward a multimarkers strategy</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>250</fpage>
          <lpage>2</lpage>
          <issue>3</issue>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4.      Antman EM, Cohen M, Bernink PJLM, McCable CH, Horacek T, Papuchis G, et al.      The TIMI risk score for unstable angina/ non-ST elevation MI. A method for      prognostication and therapeutic decision making. JAMA. 2000;284(7):835-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The TIMI risk score for unstable angina/ non-ST elevation MI: A method for prognostication and therapeutic decision making</article-title>
          <source>JAMA</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>835</fpage>
          <lpage>42</lpage>
          <issue>7</issue>
          <volume>284</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Antman</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bernink</surname>
              <given-names>PJLM</given-names>
            </name>
            <name>
              <surname>McCable</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Horacek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Papuchis</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5.      Morrow DA, Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, Dibattiste PM,      et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable      angina / non-ST-elevation myocardial infarction: B-type natriuretic peptide      and prognosis in TACTICS &#8211; TIMI 18. J Am Coll Cardiol. 2003;41(8):1264-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of B-type natriuretic peptide for risk assessment in unstable angina / non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS - TIMI 18</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1264</fpage>
          <lpage>72</lpage>
          <issue>8</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sabatine</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Demopoulos</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Dibattiste</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6.      Mayer Jr O, Simon J, Pl&#225;skova M, Cifkova R, Trefil L. N-terminal pro      B-type natriuretic peptide as prognostic marker for mortality in coronary      patients without clinically manifest heart failure. Eur J Epidemiol. 2009;24(7):363-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure</article-title>
          <source>Eur J Epidemiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>363</fpage>
          <lpage>8</lpage>
          <issue>7</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mayer Jr</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pl&#225;skova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cifkova</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Trefil</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7.      Filippi CR, Seliger SL. Biomarkers for prognostication after acute coronary      syndromes.New times and statistics[Editorial]. J Am Coll Cardiol.2009;54(4):365-7.</mixed-citation>
        <element-citation publication-type="journal">
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>365</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>54</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Filippi</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Seliger</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8.      Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability      of minor elevations of troponins I and T to predict benefit from an early      invasive strategy in patients with unstable angina and non-ST elevation myocardial      infarction: results from a randomized trial. JAMA. 2001;286(19):2405-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2405</fpage>
          <lpage>12</lpage>
          <issue>19</issue>
          <volume>286</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Rifai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Vicari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lakki</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9.      Braunwald E, Libby P, Bonow RO, Mann DL, Zipes DP. Heart disease: a textbook      of cardiovascular medicine. 8th ed. Philadelphia: WB Saunders; 2008.</mixed-citation>
        <element-citation publication-type="book">
          <source>Heart disease: a textbook of cardiovascular medicine</source>
          <date>
            <year>2008</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Third      Report&#160; of the National Cholesterol Education Program (NCEP). Expert      Panel on detection, evaluation, and treatment of high blood cholesterol in      adults (Adult treatment Panel III) final report. Circulation. 2002;106(25):3143-421.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>3143</fpage>
          <lpage>421</lpage>
          <issue>25</issue>
          <volume>106</volume>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Weber      M, Bazzino O, Estrada JLN, Fuselli JJ, Botto F, Arenaza DP, et al. N-terminal      B-type natriuretic peptide assessment provides incremental prognostic information      in patients with acute coronary syndromes and normal troponin T values upon      admission. J Am Coll Cardiol. 2008;51(12):1188-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1188</fpage>
          <lpage>95</lpage>
          <issue>12</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bazzino</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Estrada</surname>
              <given-names>JLN</given-names>
            </name>
            <name>
              <surname>Fuselli</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Botto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Arenaza</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Bassan      R, Tura BR, Maisel AS. B-type natriuretic: a strong predictor of early and      late mortality in patients with acute chest pain without ST-segment elevation      in the Emergency Department. Coron Artery Dis. 2009;20(2):143-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-type natriuretic: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the Emergency Department</article-title>
          <source>Coron Artery Dis</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>143</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bassan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tura</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Maisel</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. orrow      DA, Omland T, Lemos JA, Antman LM, Cannon CP, Hall C, et al. Prognostic value      of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with      acute coronary syndromes. Am J Cardiol. 2002;89(4):463-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>463</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>orrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Omland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Antman</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Omland      T, Person A, Ng L, O&#8217;Brien R, Karlsson T, Herlitz J, et al. N-terminal      pro- B-type natriuretic peptide and long term mortality in acute coronary      syndromes. Circulation. 2002;106(23):2913-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N-terminal pro- B-type natriuretic peptide and long term mortality in acute coronary syndromes</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2913</fpage>
          <lpage>8</lpage>
          <issue>23</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Omland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Person</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>O&#8217;Brien</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karlsson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Herlitz</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Eggers      KM, Lagerqvist B, Venger P, Wallentin L, Lindahl B. Prognostic value of biomarkers      during and non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol.      2009;54(4):357-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of biomarkers during and non-ST-segment elevation acute coronary syndrome</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>357</fpage>
          <lpage>64</lpage>
          <issue>4</issue>
          <volume>54</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Eggers</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Lagerqvist</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Venger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wallentin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lindahl</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Eren      NH, Ertas F, Yuksek U, Cakir C, Nazli C, Kseoglu M, et al. Additive prognostic      value of NT proBNP over TIMI risk score in intermediate risk patients with      acute coronary syndrome. Turk Kardyol Dern Ars. 2009;37(1):1-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Additive prognostic value of NT proBNP over TIMI risk score in intermediate risk patients with acute coronary syndrome</article-title>
          <source>Turk Kardyol Dern Ars</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Eren</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Ertas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yuksek</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Cakir</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nazli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kseoglu</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Khan      SQ, Quinn P, Davies JE, Ng LL. N-terminal pro B type natriuretic is better      than TIMI risk score at predicting death after acute myocardial infarction.      Heart.2008;94(1):40-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N-terminal pro B type natriuretic is better than TIMI risk score at predicting death after acute myocardial infarction</article-title>
          <source>Heart</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>40</fpage>
          <lpage>3</lpage>
          <issue>1</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>SQ</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Sadanandan      S, Cannon CP, Checuri K, Murphy SA, Dibattiste PM, Morrow DA, et al. Association      of elevated B-type natriuretic peptide levels with angiographic findings among      patients with unstable angina and non ST segment myocardial infarction. J      Am Coll Cardiol. 2004;44(3):564-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non ST segment myocardial infarction</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>564</fpage>
          <lpage>8</lpage>
          <issue>3</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sadanandan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Checuri</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Dibattiste</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Ndrepepa      G, Braun S, Mehilli J, Beckerath NV, Vogt W, Schomig A, et al. Plasma levels      of N-terminal pro-brain natriuretic peptide in patients with coronary artery      disease and relation to clinical presentation, angiographic severity, and      left ventricular ejection fraction. Am J Cardiol. 2005;95(5):553-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>553</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ndrepepa</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mehilli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Beckerath</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schomig</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Sabatine      MS, Morrow DA, Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes      in circulation natriuretic peptide levels in relation to myocardial ischemia.      J Am Coll Cardiol. 2004;44(10):1988-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute changes in circulation natriuretic peptide levels in relation to myocardial ischemia</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1988</fpage>
          <lpage>95</lpage>
          <issue>10</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sabatine</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Omland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Tanasijevic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Villacorta      H, Duarte A, Neilson NM, Carrano A, Mesquita ET, Hans JF, et al. Valor do      pept&#237;deo natriur&#233;tico do tipo B no diagn&#243;stico de insufici&#234;ncia      card&#237;aca congestiva em pacientes atendidos com dispneia na unidade      de emerg&#234;ncia. Arq Bras Cardiol.2002;79(6):564-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valor do pept&#237;deo natriur&#233;tico do tipo B no diagn&#243;stico de insufici&#234;ncia card&#237;aca congestiva em pacientes atendidos com dispneia na unidade de emerg&#234;ncia</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>564</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Villacorta</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Neilson</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Carrano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Hans</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Bassan      R, Putsch A, Maisel A, Rangel BT, Villacorta H, Nogueira MV, et al. B-type      natriuretic peptide: a novel early blood marker of acute myocardial infarction      in patients with chest pain and no ST-segment elevation. Eur Heart J. 2005;26(3):234-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>234</fpage>
          <lpage>40</lpage>
          <issue>3</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bassan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Putsch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maisel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rangel</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Villacorta</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>MV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Mayer      Jr O, Simon J, Pl&#225;skova M, Cifkova R, Trefil L. N-terminal pro B-type      natriuretic peptide as prognostic marker for mortality in coronary patients      without clinically manifest heart failure. Eur J Epidemiol. 2009;24(7):363-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure</article-title>
          <source>Eur J Epidemiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>363</fpage>
          <lpage>8</lpage>
          <issue>7</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mayer Jr</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pl&#225;skova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cifkova</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Trefil</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Richard      AM, Nicholls G, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma      n-terminal brain natriuretic peptide and adrenomedullin. New neurohormonal      predictors of left ventricular function and prognosis after myocardial infarction.      Circulation. 1998;97(19):1921-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma n-terminal brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1921</fpage>
          <lpage>9</lpage>
          <issue>19</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Richard</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yandle</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Frampton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Espiner</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Talwar      S. Profile of plasma N-terminal pro BNP following acute myocardial infarction:      correlation with left ventricular systolic dysfunction. Eur Heart J. 2000;21(8):1514-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Profile of plasma N-terminal pro BNP following acute myocardial infarction: correlation with left ventricular systolic dysfunction</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1514</fpage>
          <lpage>21</lpage>
          <issue>8</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Talwar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26&#160;&#160;      Verg&#233;s B, Zeller M, Desgr&#233;s J, Dental G, Laurent Y, Janin-Manificat      L, et al. High plasma N-terminal pro-brain natriuretic peptide level found      in diabetic patients after myocardial infarction is with an increased risk      of in hospital mortality and cardiogenic shock. Eur Heart J. 2005;26(17):1734-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is with an increased risk of in hospital mortality and cardiogenic shock</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1734</fpage>
          <lpage>41</lpage>
          <issue>17</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verg&#233;s</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zeller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Desgr&#233;s</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dental</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Janin-Manificat</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Lemos      JA, Morrow DA, Bentley JH. The prognostic value of B-type natriuretic peptide      in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1014</fpage>
          <lpage>21</lpage>
          <issue>14</issue>
          <volume>345</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Bentley</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28.      Sabatine MS, Morrow DA, Lemos JA, Omland T, Desai MY, Tanasijevic M, et al.      Acute changes in circulation natriuretic peptide levels in relation to myocardial      ischemia. J Am Coll Cardiol. 2004;44(10):1988-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute changes in circulation natriuretic peptide levels in relation to myocardial ischemia</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1988</fpage>
          <lpage>95</lpage>
          <issue>10</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sabatine</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Omland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Tanasijevic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Prognostic value of B-type natriuretic peptide in the mortality of patients with Acute Coronary Syndrome</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The prognostic value of BNP in acute coronary syndrome (ACS) has been repeatedly assessed, but not completely well established. Literature data for establishing the best time for assessing BNP, be it on hospital admission or after coronary intervention, are controversial. OBJECTIVE: To analyze BNP in non-ST segment elevation ACS (NSTE-ACS) in the long term, and to assess the association between BNP (pg/ml), death, coronary anatomy, and TIMI Risk Score. METHODS: Forty patients with NSTE-ACS and troponin&gt;0.50 ng/ml had their BNP levels measured on admission and 96 hours after, and were followed up for four years. The difference between the two measures was assessed by use of Wilcoxon test (p&lt;0.05). The ROC curve was used to evaluate 96-hour BNP accuracy as a death predictor, and logistic regression was used to assess a possible confounding factor among 96-hour BNP, age, and outcome. RESULTS: There was an increase in the 96-hour BNP (148 on admission vs. 267 after 96 hours; p=0.04). Thirteen patients died. For the 300 pg/ml cutoff, 96-hour BNP was a death predictor (sensitivity, 92.30%; specificity, 77.80%; positive predictive value, 66.70%; negative predictive value, 95.50%). The area under the ROC curve was 0.92. A 7.4-time increase in the relative risk of death in four years was observed with a 96-hour BNP&gt; 300 pg/ml (95% CI 1.90 a 29.30 p&lt;0.01). An association between 96-hour BNP and TIMI Risk Score was observed (p&lt;0.01). An association was observed between the increase in 96-hour BNP and multivessel disease (p=0.02). CONCLUSION: In NSTE-ACS with positive troponin, 96-hour BNP can be a tool for risk stratification. (Arq Bras Cardiol. 2012; [online].ahead print, PP.0-0)</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Prognosis</kwd>
        <kwd>natriuretic peptides</kwd>
        <kwd>acute coronary syndrome</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p><undefined id="topo-body2"/>Prognostic value of B-type natriuretic peptide in the mortality of patients with Acute Coronary Syndrome</p>
      <p>
        <bold>Alexandre Vaz Scotti; Bernardo Rangel Tura; Ronilson Gon&#231;alves Rocha; Denilson Campos de Albuquerque</bold>
      </p>
      <p> Instituto DOr de Ensino e Pesquisa; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brazil</p>
      <p>Correspondence</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> The prognostic value of BNP in acute coronary syndrome (ACS) has been repeatedly assessed, but not completely well established. Literature data for establishing the best time for assessing BNP, be it on hospital admission or after coronary intervention, are controversial.</p>
      <p><bold>OBJECTIVE:</bold> To analyze BNP in non-ST segment elevation ACS (NSTE-ACS) in the long term, and to assess the association between BNP (pg/ml), death, coronary anatomy, and TIMI Risk Score.</p>
      <p><bold>METHODS:</bold> Forty patients with NSTE-ACS and troponin&gt;0.50 ng/ml had their BNP levels measured on admission and 96 hours after, and were followed up for four years. The difference between the two measures was assessed by use of Wilcoxon test (p&lt;0.05). The ROC curve was used to evaluate 96-hour BNP accuracy as a death predictor, and logistic regression was used to assess a possible confounding factor among 96-hour BNP, age, and outcome.</p>
      <p><bold>RESULTS:</bold> There was an increase in the 96-hour BNP (148 on admission vs. 267 after 96 hours; p=0.04). Thirteen patients died. For the 300 pg/ml cutoff, 96-hour BNP was a death predictor (sensitivity, 92.30%; specificity, 77.80%; positive predictive value, 66.70%; negative predictive value, 95.50%). The area under the ROC curve was 0.92. A 7.4-time increase in the relative risk of death in four years was observed with a 96-hour BNP&gt; 300 pg/ml (95% CI 1.90 a 29.30 p&lt;0.01). An association between 96-hour BNP and TIMI Risk Score was observed (p&lt;0.01). </p>
      <p> An association was observed between the increase in 96-hour BNP and multivessel disease (p=0.02).</p>
      <p><bold>CONCLUSION:</bold> In NSTE-ACS with positive troponin, 96-hour BNP can be a tool for risk stratification. (Arq Bras Cardiol. 2012; [online].ahead print, PP.0-0)</p>
      <p><bold>Keywords</bold>: Prognosis; natriuretic peptides; acute coronary syndrome / mortality.</p>
      <p>
        <bold>Introduction </bold>
      </p>
      <p>In USA and Europe, approximately fifteen million people are admitted to emergency units each year with symptoms suggestive of acute coronary syndrome (ACS)<sup>1</sup>. Acute coronary syndrome is characterized by its complexity and multiple physiopathological causes, such as plaque rupture with acute thrombosis, progressive mechanical obstruction, unstable secondary angina, inflammation, and dynamic obstruction (coronary vasospasm)<sup>2</sup>.</p>
      <p>The strategy of multiple markers has recently been studied for ACS assessment, and includes, in addition to troponin as a myocardial necrosis indicator, other elements such as natriuretic peptides (BNP and NT pro-BNP) as hemodynamic stress markers, C reactive proteins a marker of inflammatory activity, and creatinine clearance as an indicator of endothelial injury<sup>3</sup>.</p>
      <p>Aiming at refining prognosis and guiding clinical interventions, Antman et al.<sup>4</sup> have proposed the point score known as TIMI Risk Score for ACS patients. The synergism of this set of markers could constitute a useful tool for understanding the prognosis of such a heterogeneous syndrome. The use of statistics to analyze the prognosis predicted by BNP and NT pro-BNP has been demonstrated in non-ST elevation ACS (NSTE-ACS), including patients with neither clinical evidence of left ventricle failure nor increased myocardial necrosis markers (troponin)<sup>5-6</sup>. Studies have demonstrated the potential of BNP and NT pro-BNP for providing additional information to traditional markers of ischemia subendocardial or subepicardial lesions on electrocardiography and assessment of regional left ventricular wall motion abnormalities on 1D/2D transthoracic echocardiography) and of myocardial necrosis (troponin) in ACS<sup>7</sup>.</p>
      <p>Considering the heterogeneity of ACS and its impact on mortality worldwide and in Brazil, this study suggests the routine use of BNP after coronary intervention for risk stratification in NSTE-ACS with positive troponin, assessing the value of that peptide in the long-term prognosis of high-risk patients. </p>
      <p>In addition, this study assesses the existence of an association between BNP and the three-vessel coronary anatomy, as well as the association between BNP and TIMI Risk Score. </p>
      <p>
        <bold>Methodology</bold>
      </p>
      <p>
        <bold>Study population</bold>
      </p>
      <p>This single-center study assessed 46 consecutive patients with high-risk NSTE-ACS and positive troponin, admitted to the Chest Pain Unit (CPU) of the Hospital CopaD&#8217;Or, in the city of Rio de Janeiro, Brazil, from May 2003 to January 2004. Six patients were excluded from the study as follows: two because of death within the first 96 hours after admission, and four because of not undergoing invasive stratification. Forty patients completed the study.</p>
      <p>The study follow-up extended over a period of four years after the patients&#8217; selection and consisted in the administration of a questionnaire by phone every six months. In case of an abnormal event, the study researchers were notified so that they could assess the event. This study was approved by the Committee on Ethics and Research of the institution.</p>
      <p>
        <bold>Patient Selection</bold>
      </p>
      <p>During the initial consultation at the emergency unit, the following inclusion criteria were considered: </p>
      <p>a) Presence of NSTE-ACS and increased troponin I (&gt;0.5ng/ml)<sup>8</sup> as a high-risk factor;</p>
      <p> b) Admission to the CPU and transference to the Cardiac Intensive Care Unit within the first 24 hours of symptom onset, with monitoring of progress;</p>
      <p> c) Invasive stratification in the first 24 hours after admission;</p>
      <p> d) Signing the written informed consent.</p>
      <p>After that, complementary tests were requested and the treatment strategy was defined.</p>
      <p>The exclusion criteria were as follows:</p>
      <p>a) Contraindication for angiographic study or indication of conservative treatment by attending physician;</p>
      <p> b) Death within the first 96 hours after admission;</p>
      <p> c) Presence of concomitant heart valvular disease;</p>
      <p> d) Kidney failure defined as estimated creatinine clearance&lt; 50ml/min, calculated by use of the Cockroft-Gault<sup>9</sup> formula;</p>
      <p> e) Left ventricular dysfunction (EF&#8804;50% by Simpson&#8217;s rule), either symptomatic or not.</p>
      <p>
        <bold>Procedures</bold>
      </p>
      <p>Collection of blood samples for assessing BNP and troponin I. The Blood samples were collected to measure BNP on admission and 96 hours after that. The 96 hours following hospital admission were defined as the period in which BNP could indicate the final product of coronary intervention, being, thus, a more specific tool for analyzing long-term prognosis than BNP on admission. The immunofluorescence assay Triage BNP test (Biosite Diagnostics, San Diego, CA, USA) was used. </p>
      <p>The Troponin I was assessed on admission and four hours after by using an enzymatic method (Dade Behring kit) and the Immulite device. The highest value was considered for the study. The reference value adopted was &lt; 0.5ng/ml.</p>
      <p>The TIMI Risk Score<sup>4</sup> of the patients was calculated by adding the points, according to the medical history and clinical presentation. </p>
      <p>The risk factors for CAD, such as systemic hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking, have been well defined in the medical literature<sup>10</sup>.</p>
      <p>The 12-lead ECG was performed on admission and four hours after that. Patients with ST-segment elevation on ECG were excluded. Later, ECG was repeated daily during stay at the Cardiac Intensive Care Unit.</p>
      <p>All patients underwent transthoracic echocardiography within the first 12 hours of admission, according to the chest pain protocol of the institution where the study was conducted. </p>
      <p>Invasive stratification with coronary angiography was performed within the first 24 hours after admission. </p>
      <p>A lesion of the left main coronary artery &#8805;50% or a proximal lesion of the anterior descending (AD) and circumflex (CX) coronary arteries &#8805;70% was considered to correspond to an extensive myocardial area at risk for ischemia and multivessel disease.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>The Wilcoxon test was used with a 95% confidence interval and a p value of &lt;0.05 was considered significant for analyzing BNP levels on admission and 96 hours after that. </p>
      <p>The Pearson chi-square test was used to analyze possible clinical characteristics involved with the outcome. The ROC curve was used to identify the best BNP cutoff point as a cardiac death predictor. </p>
      <p>The Logistic regression analysis was used to assess a possible confounding factor among age, 96-hour BNP, and outcome.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The population of this study consisted of 40 patients (men, 55.00%), with a mean age of 69.08&#177;11.40 years. <xref ref-type="table" rid="aop04612_ing_t1-body2">Table 1</xref> shows the clinical, electrocardiographic, and echocardiographic characteristics of the group studied. Regarding the therapeutic strategy on hospital admission, twenty-three patients underwent coronary angioplasty, ten patients underwent myocardial revascularization, and seven patients underwent only clinical treatment.</p>
      <p content-type="asset">
        <table-wrap id="aop04612_ing_t1-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt01-en.jpg"/></table-wrap>
      </p>
      <p>The TIMI Risk Score of 75.00% of the patients ranged from 4 to 6, confirming the risk profile of the patients in this study.</p>
      <p>A clear association of the TIMI Risk Score with the 96-hour BNP value was observed (p&lt;0.01), but not with the BNP value measured on admission. </p>
      <p><xref ref-type="fig" rid="aop04612_ing_f1-body2">Figure 1</xref> depicts a graph that clearly demonstrates the association between the TIMI Risk Score and the 96-hour BNP value.</p>
      <p content-type="asset">
        <fig id="aop04612_ing_f1-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gf01-en.jpg"/></fig>
      </p>
      <p>Analyzing the forty coronary angiographies, twenty-four (60.00%) met the above-specified criteria for an extensive myocardial area at risk for ischemia, while sixteen (40.00%) coronary angiographies lacked that finding. </p>
      <p>In the presence of an extensive myocardial area at risk for ischemia (<xref ref-type="table" rid="aop04612_ing_t2-body2">Table 2</xref>), an important increase in the prevalence of segmental dysfunction on echocardiography was observed (p=0.03), in addition to ECG alterations suggestive of myocardial ischemia (p=0.01).</p>
      <p content-type="asset">
        <table-wrap id="aop04612_ing_t2-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt02-en.jpg"/></table-wrap>
      </p>
      <p>Comparing the two BNP values (on admission and after 96 hours) and coronary artery anatomy, a significant difference (p=0.02) was observed in the BNP values (on admission and after 96 hours) in the group of patients with an extensive myocardial area at risk for ischemia. On the other hand, in the group of patients with no damage to the left main coronary artery or its equivalent, no significant difference was observed in the BNP values (p=0.06) (<xref ref-type="fig" rid="aop04612_ing_f2-body2">Figure 2</xref>).</p>
      <p content-type="asset">
        <fig id="aop04612_ing_f2-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gf02-en.jpg"/></fig>
      </p>
      <p>During the four-year follow-up, thirteen patients died, four of whom had sudden death. The other nine patients died during hospitalization due to recurrence of ACS, the causes of death being as follows: sepsis, five patients; stroke, two; entero-mesenteric infarction, one; and heart failure, one patient. </p>
      <p>Comparing the clinical and electrocardiographic findings of deceased patients and those of live patients after a four-year follow-up, only more advanced age could be related to the death outcome (<xref ref-type="table" rid="aop04612_ing_t3-body2">Table 3</xref>). The ROC curve showed that the 96-hour BNP cutoff point of 300.00 pg/ml most clearly distinguished patients at higher risk for death during the four-year follow-up. For that cutoff point, sensitivity was 92.30%, specificity was 77.80%, positive predictive value was 66.70%, and negative predictive value was 95.50%. </p>
      <p content-type="asset">
        <table-wrap id="aop04612_ing_t3-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt03-en.jpg"/></table-wrap>
      </p>
      <p>The area under the curve was 0.92, (95% CI 90.20&#8594;94.80; p&lt;0.01), indicating good accuracy (<xref ref-type="fig" rid="aop04612_ing_f3-body2">Figure 3</xref>). </p>
      <p content-type="asset">
        <fig id="aop04612_ing_f3-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gf03-en.jpg"/></fig>
      </p>
      <p>To assess a possible confounding factor among age, BNP, and outcome, logistical regression was used. For each ten-year increase in age, no contribution to the death outcome was observed. However, 96-hour BNP proved to be an important mortality predictor for the cutoff point of 300 pg/ml, with a ten-time increased risk ratio (<xref ref-type="table" rid="aop04612_ing_t4-body2">Table 4</xref>). The analysis of the BNP accuracy on admission, that is, within 24 hours after the coronary event, did not reach significance. Assessing the cutoff point of 274 pg/ml, resulted in sensitivity of 46.20%, specificity of 85.20%, positive predictive value of 60.00%, and negative predictive value of 76.70%. The area under the curve was 0.65, which did not indicate good accuracy. As 96-hour BNP represents the result of the therapeutic intervention, we believe that, in our study, 96-hour BNP can be more specific than BNP on admission for the association with long-term prognosis. </p>
      <p content-type="asset">
        <table-wrap id="aop04612_ing_t4-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0605-00050-gt04-en.jpg"/></table-wrap>
      </p>
      <p>We observed a relative risk of 7.44 (95% CI 1.89&#8594;29.28) in the group of patients with 96-hour BNP higher than 300.00 pg/ml. However, we meet a large CI, perhaps with a more significant number of patients, could to establish a better association with our findings. </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>This study showed that the BNP measured 96 hours after admission, using 300 pg/ml as the cutoff point, associated with the significant relative risk of death of 7.44 (95% CI 1.89&#8594;29.28) during the four-year follow-up. The area under the ROC curve was 0.92, showing a good accuracy. This finding is in accordance with other studies in the literature, such as those by Weber et al. and Bassan et al.<sup>11-15</sup>, showing the statistical power and importance of natriuretic peptides as predictors of cardiac death in ACS patients.</p>
      <p>The age was the only variable that could be associated with outcome, although no relation is known to exist between age bracket and high serum BNP levels. Moreover, the logistic regression analysis has shown that age, 96-hour BNP, and outcome are not associated.</p>
      <p>Considering the 96-hour BNP cutoff point of 300pg/ml, <xref ref-type="table" rid="aop04612_ing_t4-body2">Table 4</xref> shows a ten-time greater risk ratio then each ten-year increase in age.</p>
      <p>It is worth stressing that the analysis of the accuracy of the BNP on admission could not discriminate a significant cutoff point to estimate the risk of events during the follow-up period. This was not observed in the study by Bassan et al.<sup>12</sup>, which used the BNP on admission to distinguish the cutoff point as an early and late mortality predictor. Our hypothesis is that 96-hour BNP can be a marker more compatible with the real world in the long-run, because it is the result of the therapeutic approach. As all patients in this study underwent coronary intervention within the first 24 hours after the ischemic event, at the end of 96 hours, all patients had been treated, that is, their therapeutic strategies had already been defined. However, further studies, mainly with a more significant number of patients, should be conducted to confirm that hypothesis.</p>
      <p>Eggers et al.<sup>15</sup> have reported an excellent accuracy of NT pro-BNP measured late in the course of ACS (at six weeks and after six months). Thus, in addition to being death predictors when measured during hospitalization, since natriuretic peptides can indicate the ischemic area, they can also add prognostic information when analyzed after treatment definition. </p>
      <p>This study also assessed the possible associations between the TIMI Risk Score and BNP values on admission and 96 hours after that. </p>
      <p>A clear association was noted between the 96-hour BNP and a TIMI Risk Score increase. Analyzing the graph of that association (<xref ref-type="fig" rid="aop04612_ing_f1-body2">Figure 1</xref>), the drop observed can result from the reduced number of individuals with a TIMI Risk Score of 6. We also believe that 96-hour BNP acted as an additional prognostic marker to TIMI Risk Score, which is a well defined risk stratification tool for NSTE-ACS in the short and long run<sup>4</sup>. However, two recently published studies have also shown the greater prognostic value of NT pro-BNP as compared with that of the TIMI Risk Score<sup>16-17</sup>.</p>
      <p>The literature lacks uniform criteria to quantify myocardial ischemic area in terms of BNP values. The two major studies by Sadanandan et al.<sup>18</sup> and Ndrepepa et al.<sup>19</sup> have used, as the criteria for estimating the myocardial area at risk for ischemia, the effects on the anterior descending coronary artery and the three-vessel anatomy, respectively.</p>
      <p>In our case series, the increase in BNP values 96 hours after hospital admission and coronary interventionindicated patients with larger myocardial areas at risk for ischemia and multivessel disease. The electrocardiographic alterations, ST-segment decrease and/or T-wave inversion, and echocardiographic alterations, segmental dysfunction, compatible with myocardial ischemia were more prevalent in the group of patients with multivessel disease (<xref ref-type="table" rid="aop04612_ing_t2-body2">Table 2</xref>).</p>
      <p>The previous studies have shown that a sharp increase in serum BNP levels during an ischemic event, with no evidence of systolic dysfunction, can be associated with the complexity and severity of the coronary artery anatomy. For example, Sabatine et al.<sup>20</sup> have reported, during transitory myocardial ischemia, a significant increase in serum BNP levels, and the increase was associated with the severity of the ischemic disease. </p>
      <p>In our study, a significant increase in BNP level was observed 96 hours after admission (p=0.02) in the population with larger myocardial areas at risk for ischemia and multivessel disease. We decided not to use a cutoff point, because we already had BNP levels on admission and after 96 hours; thus, the importance of the increase during the period was assessed. </p>
      <p>It is worth noting that, in our case series, the BNP levels found were higher than those reported in the literature. Analyzing some previous studies, we observed that the BNP cutoff point has been modified depending on the purpose of the research project. For diagnosing heart failure, a cutoff point of 200 pg/ml is extremely accurate<sup>21</sup>. In patients with chest pain, BNP &gt;100 pg/ml is a strong predictor of acute myocardial infarction<sup>22</sup>. For patients with NSTE-ACS, BNP serum levels higher than 80 pg/ml could associate with the severity and extension of the myocardial ischemic area<sup>18</sup>. In this study, a 300-pg/ml cutoff point for 96-hour BNP, could be the BNP representing the result of coronary intervention, defined a group of patients with more severe NSTE-ACS and a 7.4-time higher risk of death in the four-year follow-up.</p>
      <p>In a recently published study aiming at analyzing the prognosis of patients with NSTE-ACS, an admission BNP cutoff point of 101 pg/ml </p>
      <p>discriminated a relative risk of death of 13.0 in the first month and of 5.3 at one year<sup>12</sup>.</p>
      <p>Another study has reported the association between NT pro-BNP and the outcome of death in a six-year follow-up in patients with ACS and after myocardial revascularization<sup>23</sup>.</p>
      <p>The 96-hour BNP could be a useful complementary, easily-calibrated tool for risk stratification of ACS patients, particularly at places lacking hemodynamic laboratory facilities, allowing easy recognition of groups at higher risk for late adverse events.</p>
      <p>This study suggests that an increased 96-hour BNP level (&gt; 300 pg/ml) is associated with a higher risk of death during the four-year follow-up of patients with NSTE-ACS. This requires closer clinical monitoring for adjusting cardiovascular risk factors. However, the literature still lacks data justifying the use of a treatment strategy based only on the elevation of BNP levels in ACS patients. </p>
      <p>It is easy to understand the increase in BNP among ACS patients with myocardial dysfunction, because the increase in left ventricular filling pressure triggers BNP synthesis and release<sup>24-26</sup>. However, the increased risk for a cardiac event in the population with no left ventricular failure suggests the existence of other mechanisms. The diastolic dysfunction secondary to myocardial ischemia might be one of the factors behind the increase in serum BNP levels in ACS<sup>27-28</sup>.</p>
      <p>The 96-hour BNP must also be interpreted together with hemodynamic and clinical findings, ECG alterations, elevation in myocardial necrosis markers [creatinine kinase (CK) mass, and troponin], presence of segmental alterations on transthoracic echocardiogram, and inflammatory profile by use of PCR measurement.</p>
      <p>
        <bold>Limitations of the study</bold>
      </p>
      <p>This study has certain limitations. The small size of the sample could result in a selection bias. The criterion chosen to determine the extension of the myocardial area at risk of ischemia, which was lesion of the left main coronary artery and/or its equivalent, used the degree of artery obstruction as the ischemia parameter, rather than functional assessment. However, because of the clinical severity of the group studied, assessment by use of myocardial scintigraphy or cardiac magnetic resonance, which could be harmful to patients, was not performed.</p>
      <p>This study was conducted at a private institution in a prosperous district of the city of Rio de Janeiro, with patients of high socioeconomic and cultural levels. Thus, the risk can have been underestimated, because real world conditions, such as access to medical resources and medications that interfere with the course of the disease, were not considered in the analysis. </p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>1. In patients with NSTE-ACS, a BNP level higher than 300 pg/ml 96 hours after the onset of an ischemic event and of a coronary intervention is associated with a 7.44-time higher risk of death in four years.</p>
      <p>2. In this study, the greater increase in the BNP level within 96 hours from admission is associated with a greater severity in coronary artery lesion in NSTE-ACS patients. This association could explain the association between 96-hour BNP and the NSTE-ACS event.</p>
      <p>3. Our findings suggest that an association between BNP and TIMI Risk Score can exist.</p>
      <p>4. The 96-hour BNP can be a useful tool for the cardiologist to establish the long-term prognosis of patients with NSTE-ACS. However, further studies are required to confirm the best time for BNP assessment (be it on admission or after the intervention) during the hospitalization of individuals with NSTE-ACS and positive troponin. </p>
      <p>
        <bold>Acknowledgement</bold>
      </p>
      <p>We thank the Hospital Copa D&#8217;Or for their supportin serial blood collection and for funding this study. We also thank the patients and their families for providing their clinical data, thus having contributed to this study.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
